Rusan Pharma, a pharmaceutical firm, launched a brand new energetic pharmaceutical ingredient (API) facility on Saturday in Pithampur, Madhya Pradesh.
This facility is ready to supply 400 metric tonnes of APIs yearly and is predicted to create over 300 jobs. The corporate has invested Rs 300 crore within the facility, positioned throughout the Pithampur Particular Financial Zone (SEZ).
The brand new facility will increase Rusan Pharma’s present API capability, aiming to produce essential APIs to satisfy the rising demand for its dependancy therapy and ache administration merchandise in India and internationally.
The corporate is understood for growing progressive merchandise, akin to Buprenorphine Sublingual and Buprenorphine Naloxone Sublingual Tablets for drug abuse therapy, Apomorphine Injections for Parkinson’s therapy, and indigenous formulations of Fentanyl, Buprenorphine, and Lidocaine transdermal patches for average to extreme ache. Moreover, they produce Nicotine transdermal patches for tobacco cessation.
Kunal Saxena, managing director of Rusan Pharma, commented, “With an funding of about Rs 300 crore in two phases, this new API facility will increase our present API manufacturing capability from 40 metric tonnes in Ankleshwar to 400 metric tonnes in Pithampur. Our new plant options 5 modular API manufacturing blocks with devoted suites for completed API manufacturing.”
The corporate said that the present Good Manufacturing Observe (GMP) approvals for its APIs and completed formulations services have the capability to satisfy 90 per cent of the worldwide demand.
Rusan Pharma holds GMP approvals from a number of authorities, together with Well being Canada, the Therapeutic Items Administration (TGA) of Australia, the South African Well being Merchandise Regulatory Authority (SAPHRA), the European Union (EU), the United Arab Emirates (UAE), and Russia.
First Revealed: Nov 25 2023 | 6:16 PM IST